These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

600 related items for PubMed ID: 19834961

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
    Herrstedt J, Apornwirat W, Shaharyar A, Aziz Z, Roila F, Van Belle S, Russo MW, Levin J, Ranganathan S, Guckert M, Grunberg SM.
    J Clin Oncol; 2009 Nov 10; 27(32):5363-9. PubMed ID: 19805683
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM, Rolski J, Strausz J, Aziz Z, Lane S, Russo MW, Wissel P, Guckert M, Wright O, Herrstedt J.
    Lancet Oncol; 2009 Jun 10; 10(6):549-58. PubMed ID: 19428297
    [Abstract] [Full Text] [Related]

  • 4. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study Group.
    Cancer; 2003 Jun 15; 97(12):3090-8. PubMed ID: 12784346
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting.
    Roila F, Rolski J, Ramlau R, Dediu M, Russo MW, Bandekar RR, Grunberg SM.
    Ann Oncol; 2009 Nov 15; 20(11):1867-73. PubMed ID: 19541792
    [Abstract] [Full Text] [Related]

  • 7. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B.
    Breast Cancer Res Treat; 2009 Feb 15; 113(3):529-35. PubMed ID: 18327706
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study.
    Hesketh PJ, Wright O, Rosati G, Russo M, Levin J, Lane S, Moiseyenko V, Dube P, Kopp M, Makhson A.
    Support Care Cancer; 2012 Jul 15; 20(7):1471-8. PubMed ID: 21822913
    [Abstract] [Full Text] [Related]

  • 14. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA, Lembersky B, Kaywin P, Kalman L, Yocom K, Friedman C.
    Cancer J Sci Am; 1998 Jul 15; 4(1):52-8. PubMed ID: 9467047
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
    Lajolo PP, de Camargo B, del Giglio A.
    Am J Clin Oncol; 2009 Feb 15; 32(1):23-6. PubMed ID: 19194119
    [Abstract] [Full Text] [Related]

  • 18. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy.
    White L, Daly SA, McKenna CJ, Zhestkova N, Leal C, Breatnach F, Smelhaus V, Hung IJ, Kowalczyk J, Ninane J, Mitchell T, Haigh C.
    Pediatr Hematol Oncol; 2000 Sep 15; 17(6):445-55. PubMed ID: 10989464
    [Abstract] [Full Text] [Related]

  • 19. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
    Gralla RJ, de Wit R, Herrstedt J, Carides AD, Ianus J, Guoguang-Ma J, Evans JK, Horgan KJ.
    Cancer; 2005 Aug 15; 104(4):864-8. PubMed ID: 15973669
    [Abstract] [Full Text] [Related]

  • 20. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG.
    Semin Oncol; 1994 Oct 15; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.